PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Status Completed

Clinical Trial Summary

Two cohorts of patients will be enrolled: Cohort A will consist of patients who are current smokers, and Cohort B will consist of patients who are current nonsmokers. There will be 24 patients enrolled in each cohort. Nonsmokers are patients who have not consumed tobacco or nicotine-containing products for 1 year before the start of the study. Patients classified as current smokers must have smoked a minimum of 10 cigarettes per day for up to 1 year. Patients who have smoked 1-9 cigarettes per day for up to 1 year, or more than 10 cigarettes per day for less than 1 year will not be eligible for this study.

Clinical Trial Description

Compared with supportive care alone, erlotinib has been associated with improved overall survival in patients with Refractory Solid Tumors; however, this absolute benefit is limited for the majority of patients. Incorporating other biologic agents into the second- or third-line treatment setting may prove to be a successful strategy in improving treatment efficacy (which has been recently demonstrated in several tumor types). Additionally, recent data suggest that smoking may influence the pharmacokinetic (PK) profile of erlotinib by increasing the metabolic clearance. Data suggest that the geometric mean erlotinib AUC(0-inf) and C(24h) are significantly decreased in smokers compared with nonsmokers (Hamilton et al. 2006). For this reason, this trial will enroll separate cohorts of patients who are current smokers and patients who are nonsmokers. Nonsmokers are patients who have not consumed tobacco or nicotine-containing products for 1 year before the start of the study. Patients classified as current smokers must have smoked a minimum of 10 cigarettes per day for up to 1 year. ;

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Refractory Solid Tumors

Clinical Trial Details

NCT number	NCT00759928
Study type	Interventional
Source	SCRI Development Innovations, LLC
Contact
Status	Completed
Phase	Phase 1
Start date	October 2008
Completion date	June 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00404508` - A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors	Phase 2
Completed	`NCT02450136` - Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors	N/A
Completed	`NCT02596503` - A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors	Phase 1
Recruiting	`NCT06150365` - Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors	Early Phase 1
Completed	`NCT01247168` - An Open-Label, Dose-Escalation Study of AZD2461	Phase 1
Completed	`NCT00665990` - Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia	Phase 1
Completed	`NCT02691793` - Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors	Phase 4
Completed	`NCT02450149` - Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors	N/A
Completed	`NCT02691767` - Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors	N/A
Terminated	`NCT00664586` - A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors	Phase 1
Recruiting	`NCT05811975` - KSX01-TCRT Injection Project in Solid Tumors	Early Phase 1
Completed	`NCT03810742` - Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors	Phase 1
Terminated	`NCT03096340` - Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer	Phase 1
Completed	`NCT02450123` - Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors	N/A
Completed	`NCT02383368` - A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma	Phase 1
Completed	`NCT00394446` - Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors	Phase 1
Completed	`NCT03052205` - A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors	Phase 1
Completed	`NCT02482441` - A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10	Phase 1
Recruiting	`NCT03739827` - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting	`NCT05150457` - Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors	Phase 1